Dyne Therapeutics (DYN) Free Cash Flow (2019 - 2026)
Dyne Therapeutics' (DYN) quarterly Free Cash Flow came in at -$145.1 million in Q1 2026, down 35.81% year-on-year from -$226.1 million in Q1 2025, and down 29.79% on a QoQ basis from -$111.8 million in Q4 2025.
Dyne Therapeutics (DYN) Free Cash Flow (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has 8 years of Free Cash Flow data on file, last reported at -$145.1 million in Q1 2026.
- On a quarterly basis, Free Cash Flow fell 35.81% year-over-year to -$145.1 million in Q1 2026; TTM through Mar 2026 was -$460.3 million, a 43.53% decrease from a year earlier, with the FY2025 full-year figure at -$422.0 million, down 44.34% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$145.1 million, down from -$111.8 million in the prior quarter.
- Over the last five years, Free Cash Flow for DYN reached as high as -$29.3 million in Q4 2022 and fell as low as -$145.1 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$70.7 million across 5 years, with a median of -$55.9 million in 2024.
- On a YoY basis, Free Cash Flow climbed as much as 33.45% in 2022 and fell as far as 182.57% in 2022.
- Year by year, Free Cash Flow stood at -$29.3 million in 2022, then dropped by 17.36% to -$34.4 million in 2023, then plunged by 141.67% to -$83.0 million in 2024, then tumbled by 34.68% to -$111.8 million in 2025, then fell by 29.79% to -$145.1 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$145.1 million in Q1 2026, -$111.8 million in Q4 2025, and -$108.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Dyne Therapeutics | 3.94 Bn | 3.94 Bn | - | -145.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -145.14 Mn |
| Mar 31, 2026 | -145.14 Mn |
| Dec 31, 2025 | -111.83 Mn |
| Dec 31, 2025 | -111.83 Mn |
| Sep 30, 2025 | -108.53 Mn |
| Sep 30, 2025 | -108.53 Mn |
| Jun 30, 2025 | -94.76 Mn |
| Jun 30, 2025 | -94.76 Mn |
| Mar 31, 2025 | -106.87 Mn |
| Mar 31, 2025 | -106.87 Mn |
| Dec 31, 2024 | -83.03 Mn |
| Dec 31, 2024 | -83.03 Mn |
| Sep 30, 2024 | -74.88 Mn |
| Sep 30, 2024 | -74.88 Mn |
| Jun 30, 2024 | -55.89 Mn |
| Jun 30, 2024 | -55.89 Mn |
| Mar 31, 2024 | -78.56 Mn |
| Mar 31, 2024 | -78.56 Mn |
| Dec 31, 2023 | -34.36 Mn |
| Dec 31, 2023 | -34.36 Mn |